Lipoxin
|
WikiDoc Resources for Lipoxin |
|
Articles |
|---|
|
Most recent articles on Lipoxin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Lipoxin at Clinical Trials.gov Clinical Trials on Lipoxin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Lipoxin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Lipoxin Risk calculators and risk factors for Lipoxin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Lipoxin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Lipoxins are a series of anti-inflamatory mediators. Lipoxins are short lived endogenously produced eicosanoids whose appearance in inflammation signals the resolution of inflammation. During the acute inflammatory process, the proinflammatory cytokines such as IFN-γ and IL-1β can induce the expression of anti-inflammatory mediators such as lipoxins (LXs) and IL-4, which promote the resolution phase of inflammation.[1]
They are abbreviated as LX, an acronym for lipoxygenase (LO) interaction products.
Lipoxins are derived from arachidonic acid, an ω-6 fatty acid
An analogous class, the resolvins, is derived from EPA and DHA, ω-3 fatty acids.[2]
At present two lipoxins have been identified; lipoxin A4 (LXA4) and lipoxin B4 (LXB4).
Lipoxins, as well as certain peptides, are high affinity (sub nanomolar) ligands for the lipoxin A4 receptor (ALXR), which was first identified based on sequence homology as the formyl peptide receptor like receptor (FPRL1). Lipoxin signaling through the ALXR inhibits chemotaxis, transmigration, superoxide generation and NF-kB activation.[3]
Conversely, peptide signalling through the same receptor, in vitro, has been shown to stimulate chemotaxis of PMN and calcium mobilization.[3] The peptides that have ALXR affinity tend to be signals for leukocyte migration and subsequent phagocytosis such as acute phase proteins, bacterial peptides, HIV envelope proteins and neurotoxic peptides.
Lipoxins are also high affinity antagonists to the cystienyl leukotriene receptor 1 (CysLT1) to which several leukotrienes (LTC4, LTD4 and LTE4) mediate their smooth muscle contraction and eosinophil chemotactic effects. The CysLT1 receptor is also the site of action for the asthma drug, Montelukast(Singulair)[4]
References
- ↑ McMahon, Blaithin and Godson, Catherine. "Lipoxins: endogenous regulators of inflammation". Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Unknown parameter|publishdate=ignored (help); Unknown parameter|accessmonthday=ignored (help) Invited review article. - ↑ Charles N. Serhan, Mats Hamberg, and Bengt Samuelsson (September 1, 1984). "Lipoxins: Novel Series of Biologically Active Compounds Formed from Arachidonic Acid in Human Leukocytes". Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Unknown parameter|accessmonthday=ignored (help) Original description of lipoxins. - ↑ 3.0 3.1 Chiang N., Arita M., and Serhan CN. (2005). "Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX". Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Unknown parameter|publishdate=ignored (help); Unknown parameter|accessmonthday=ignored (help) - ↑ Drazen J., Israel E., and O'Byrne P. (1999). "Treatment of Asthma with Drugs Modifying the Leukotriene Pathway". PMID 9895400. Unknown parameter
|publishdate=ignored (help);|access-date=requires|url=(help)
External links
- Lipoxins at the US National Library of Medicine Medical Subject Headings (MeSH)